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Purpose: Fingolimod is among the ﬁrst oral disease-modifying agents for the treatment of relapsing-
remitting multiple sclerosis (MS). Despite its favorable safety proﬁle, ﬁngolimod may cause macular
edema, a signiﬁcant adverse event, which occurs within the ﬁrst 4 months of therapy. Macular edema
usually resolves upon discontinuation of ﬁngolimod; however, the time required for resolution of this
condition is unknown.
Observations: A 42-year-old white male with a history of relapsing-remitting MS presented with blurring
of vision in his left eye 24 h after the ﬁrst dose of ﬁngolimod. Dilated fundus examination of the left eye
revealed an increased retinal thickness and mild optic disc pallor. Spectral domain optical coherence
tomography (SD-OCT) conﬁrmed the diagnosis of cystoid macular edema. Topical nonsteroidal anti-
inﬂammatory drug (NSAID) was initiated immediately after the diagnosis, and ﬁngolimod therapy was
discontinued shortly thereafter. Seven weeks after the initial presentation, intermediate uveitis was
noted in the inferior periphery of the left eye, and SD-OCT revealed worsening of macular edema.
Acetazolamide therapy was added to the topical NSAID to control the edema. Three weeks after initiation
of acetazolamide, macular thickness reduced signiﬁcantly. The patient then stopped all medications, and
3 weeks later macular edema rebounded. Systemic steroid was employed to control both the interme-
diate uveitis and macular edema.
Conclusions and importance: We report a case of acute and very rapid onset of ﬁngolimod-associated
macular edema (FAME). Acetazolamide may have a beneﬁcial effect on macular edema secondary to
ﬁngolimod. It is unclear if intermediate uveitis is associated with the rapid development of FAME.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fingolimod is among the ﬁrst oral disease-modifying thera-
peutic agents approved by the United States Food and Drug
Administration for the treatment of the relapsing-remitting form of
multiple sclerosis (MS).1 It is a sphingosine-1-phosphate (S1P) re-
ceptor modulator that decreases the release of lymphocytes from
peripheral lymphoid organs to systemic circulation, thereby
reducing the immune-mediated inﬁltration of these lymphocytes
into the central nervous system.2 Macular edema is a signiﬁcant
ocular adverse event reported in randomized clinical trials ofand Reading Center, Omaha,
yen).
Inc. This is an open access article uﬁngolimod therapy for multiple sclerosis. The overall incidence of
ﬁngolimod-associated macular edema (FAME) after a 0.5-mg dose
in both the FREEDOMS and TRANSFORMS trials was 0.2%.3 Several
lines of evidence suggest that ﬁngolimod increases vascular
permeability via its effect on endothelial S1P receptor, which ulti-
mately results in FAME.4,5 Diabetes and prior history of uveitis were
found to be associated with increased risk of developing FAME in
initial clinical studies.69 Most cases of FAME resolve spontane-
ously upon cessation of ﬁngolimod therapy. However, given a
relatively low incidence of this condition, the time period required
for spontaneous resolution remains unknown. In this report, we
describe a case of acute and very-rapid-onset FAME.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Our patient was a 42-year-old white male with an 11-year his-
tory of relapsing-remitting MS involving the brainstem and spinal
cord. The patient started to receive injectable interferon beta-1a
(IFN-b1a) soon after the diagnosis and had not had major re-
lapses or signiﬁcant side effects from IFN-b1a since. The patient had
no diabetes; his medical history was notable only for depression.
The patient sought other treatment options after being weary of
weekly intramuscular injections of IFN-b1a, severe ﬂu-like symp-
toms, persistent fatigue, and worsened episodes of pre-existing
depression. He was referred for baseline ophthalmological evalu-
ation prior to switching from IFN-b1a to ﬁngolimod. Neurological
examination was unremarkable except for a mild left foot drop.
Neuro-ophthalmological examination was normal except for re-
sidual left eye adduction saccade secondary to prior intranuclear
ophthalmoplegia, mild relative afferent pupillary defect with mild
optic nerve pallor secondary to previous episode of optic neuritis,
and epipapillary vascular frond in the left eye (Fig. 1A). Best-
corrected visual acuity (BCVA) on initial evaluation was 20/20 in
both eyes. Funduscopic examination did not reveal any peripheral
exudates, snowballs, or snow bank in both eyes. Humphrey visual
ﬁelds and spectral domain optical coherence tomography (SD-OCT)
macular thickness were within normal limits in both eyes. IFN-b1a
was stopped on the day that ﬁngolimod therapy was initiated.
Twenty-four hours after the ﬁrst 0.5-mg dose of ﬁngolimod, the
patient noticed painless blurring of vision in the left eye. The
blurring initially affected the lower part of the visual ﬁeld and
gradually progressed to a ring/donut shape. Examination con-
ducted 3 days after the initiation of ﬁngolimod therapy revealed
that the BCVA had declined to 20/30 in the left eye and remained
unchanged in the right eye. Color vision was normal in both eyes,
but contrast sensitivity was decreased in the left eye. Patient re-
ported no painwith extraocular movements in either eye. Slit lamp
examination was unremarkable in both eyes. Funduscopy revealed
dull foveal reﬂex with retinal thickening and unremarkable pe-
riphery in the left eye. Diagnosis of macular edema was conﬁrmedFig. 1. Color fundus photograph of the left eye (A; initial fundus exam) and ﬂuorescein angio
macular edema). A: Dilated tortious vascular frond projecting into the vitreous and glial t
periphery. C: Cystoid macular edema with hyperﬂuorescence inferonasal to the optic disc, co
the nasal part of the optic disc. D: Perivascular leakage of retinal vessels in the inferior perwith SD-OCT, which demonstrated increased central macular
thickness (CMT) of 501 mm, multiple intraretinal cystic spaces, and
mild subretinal ﬂuid (Fig. 2B) in the left eye. Immediately after the
diagnosis, treatment with a topical nonsteroidal anti-inﬂammatory
drug (NSAID) was started in the left eye. Fingolimod therapy was
discontinued 3 days later by the neurologist after discussing other
treatment options with the ophthalmologist and the patient. At the
2-week follow-up visit, after the diagnosis of FAME was made, the
BCVA in the left eye remained stable; however, SD-OCT revealed
worsening of macular edema with increased subretinal ﬂuid and
CMT to 613 mm (Fig. 2C). Four weeks after FAME was diagnosed,
there remained subtle change in the macular edema with CMT of
590 mm; thus, topical dorzolamide was added. Three weeks later,
fundus examination of the left eye revealed snowballs and snow-
banks in the inferior periphery (Fig. 1B). Fluorescein angiography
(FA) showed characteristic petaloid pattern of cystoid macular
edema in the left eye along with perivascular leakage from the
inferior peripheral vessels, hyperﬂuorescence of the dilated
tortious epipapillary vascular frond, and staining of the optic nerve
head (Fig. 1C and D). Macular edema was persistent with CMT of
550 mm. SD-OCT and FA of the right eye were unremarkable. A
systemic carbonic anhydrase inhibitor, acetazolamide, in a dose of
500 mg twice daily was added to the current therapy. Three weeks
after acetazolamide was added, the left eye showed signiﬁcant
reduction in the CMT to 331 mmwith restoration of foveal contour,
disappearance of intraretinal cysts, and resolution of the subretinal
ﬂuid (Fig. 2D). The BCVA in the left eye improved to 20/25 þ 3.
Following this improvement, the patient was instructed to continue
treatment for 2 additional weeks and then taper acetazolamide to
250 mg twice daily. Despite these instructions, the patient stopped
all medications. Three weeks later, SD-OCT detected recurrence of
macular edema with a slight decline of BCVA to 20/25e2 in the left
eye (Fig. 2E). In addition, fundus examination revealed persistent
snowballs and snowbanks; similar to previous angiogram, FA
continued to show macular leakage, periphlebitis, and staining of
the optic disc in the left eye. Therapy with 40-mg/day oral pred-
nisone was initiated to control both the periphlebitis and maculargrams (FA) of the left eye (B, C, and D; initial FA after diagnosis of ﬁngolimod-associated
issue inferonasal and nasal to the optic disc, respectively. B: Snowballs in the inferior
rresponding to the dilated tortious vessel seen on the color photograph and staining of
iphery.
Fig. 2. Spectral domain optical coherence tomography images. A: Unremarkable macular appearance at baseline. B: Macular edema with minimal subretinal ﬂuid right after
ﬁngolimod administration. C: Worsening of macular edema with increased subretinal ﬂuid 2 weeks after stopping ﬁngolimod. D: Resolution following acetazolamide supple-
mentation. E: Rebound of macular edema 3 weeks after acetazolamide cessation.
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During the follow-up visit 8 weeks later, resolution of macular
edema and decreased perivascular leakage were noted. Prednisone
was continuously tapered to 5 mg/day, and the patient remained
clinically stable without recurrence of uveitis or macular edema.3. Discussion
To the best of our knowledge, this is the ﬁrst report of the
earliest case of FAME, occurring within 24 (based on symptoms) to
72 (based on SD-OCT) hours after initiation of ﬁngolimod. The
report also highlights the potential role of systemic carbonic
anhydrase inhibitor in the management of FAME.
Apart from cessation of ﬁngolimod therapy, there is no
consensus about the optimal management of FAME. In the clinical
trials of ﬁngolimod for MS (TRANSFORMS and FREEDOMS),
approximately 80% cases of FAME resolved spontaneously
following cessation of the 0.5-mg ﬁngolimod therapy.10,11 In these
trials, only 1 participant with FAME did not show improvement
after ﬁngolimod cessation, but detailed description and long-term
follow-up of this case were lacking. Topical NSAIDs have been
used to hasten the resolution of FAME with reports of edema res-
olutionwithin 1month of treatment. The potential beneﬁt of NSAID
therapy is edema resolution within 1 month as opposed to 4
months that may be needed for edema resolution after ﬁngolimod
cessation alone.12 However, based on the currently available case
reports, the natural course of FAME cannot be fully elaborated, and
thus, it is unknown whether NSAID therapy is beneﬁcial.
It is often challenging to demonstrate whether a certain treat-
ment is effective or not, especially when macular edema can
resolve spontaneously with discontinuation of ﬁngolimod, leaving
one to wonder whether time or therapy has led to edema resolu-
tion. In our case, worsening of macular edema occurred despite
cessation of ﬁngolimod and use of topical NSAIDs for more than 1
month. On the other hand, addition of acetazolamide resulted in
signiﬁcant decline in macular thickness and resolution of the
intraretinal cysts within 3 weeks. Since acetazolamide for the
treatment of FAME has shown beneﬁts in a recent report,13 we
opted for such therapy after noting the failure of topical treatment
and before proceeding with systemic steroid or invasive therapy
such as intravitreal or sub-Tenon's steroid. Recurrence of macular
edema after tapering acetazolamide treatment was previouslydescribed by Schr€oder et al.13 In our case, premature discontinua-
tion of acetazolamide and persistent intermediate uveitis may have
contributed to this recurrence.
Development of intermediate uveitis after ﬁngolimod adminis-
tration is perplexing. IFN-b, previously used to treat relapsingMS in
this patient, is known to be effective in controlling intermediate
uveitis and CME associated with MS.14,15 Thus, the abrupt discon-
tinuation of IFN-b, rather than the commencement of ﬁngolimod,
might have led to recurrence of uveitis. In addition, it is possible
that IFN-b cessation might have played a role in the rapid devel-
opment of FAME in this patient. Also, subclinical or prior inter-
mediate uveitis might have contributed to the acute onset of FAME.
Several facts support this possibility. First, prior history of uveitis is
associated with an increased risk of FAME, according to previous
MS trials.3 Second, it is possible that active intraocular inﬂamma-
tion existed but was insufﬁciently severe to be detected by clinical
examination prior to ﬁngolimod initiation. This existing inﬂam-
mation could have precipitated the very rapid onset of macular
edema following ﬁngolimod initiation. Also, worsening of edema
even after ﬁngolimod discontinuation and recurrence of edema
after acetazolamide cessation imply that an underlying inﬂamma-
tory component, not just ﬁngolimod, might have contributed to
edema.
Currently, sufﬁcient data on the use of ﬁngolimod in the setting
of active or prior intermediate uveitis are lacking; it is unknown if a
pervious episode or active inﬂammation in the peripheral retina
has any role in precipitating acute FAME as seen in this case.
In conclusion, FAME may occur very rapidly after initiation of
ﬁngolimod therapy. Acetazolamide may be considered as an option
for the treatment of FAME before other, more invasive therapeutic
options are explored. Careful examination of the peripheral retina
to detect signs of intermediate uveitis is warranted before ﬁngoli-
mod initiation. IVFA to detect retinal periphlebitis may be consid-
ered as a baseline evaluation prior to ﬁngolimod administration to
exclude active uveitis, a potential risk factor for the acute devel-
opment of FAME.Patient consent
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